ReviewScience China. Life sciences2026
The role of microbial enzymes in intervention strategies for metabolic diseases targeting the gut microbiota.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic diseases-including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM), atherosclerosis (AS), and polycystic ovary syndrome (PCOS)-pose a significant global health crisis due to their rapidly increasing prevalence. The therapeutic potential of the gut microbiota and its metabolites is gaining recognition, with microbial enzymes playing a pivotal role. These enzymes catabolize dietary fibers into mono- and oligo-saccharides, ultimately yielding beneficial short-chain fatty acids, while concurrently converting phytochemicals into absorbable, bioactive small molecules. An increasing array of small-molecule agonists and inhibitors has been developed to target microbial pathways, such as bile acid metabolism and trimethylamine formation. Furthermore, engineered bacteria and fecal microbiota transplantation are gaining traction as promising therapeutic strategies. This review synthesizes evidence on how microbial enzymes underpin these diverse interventions, aiming to advance the development of microbial enzyme-based management strategies for metabolic diseases.
Indexed as
Identifiers
42961559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.